Modern ideas about the etiology, pathogenesis and principles of treatment of endometrial hyperplasia
- 作者: Podzolkova N.M.1, Korennaya V.V.1
-
隶属关系:
- Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
- 期: 编号 8 (2021)
- 页面: 192-199
- 栏目: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249495
- DOI: https://doi.org/10.18565/aig.202L8.192-199
- ID: 249495
如何引用文章
详细
Endometrial hyperplasia is a complex and multifaceted problem in gynecology. The existing information on the development of endometrial hyperplasia is not sufficient and the specialists do not have a common understanding of the pathogenesis of the disease and its triggering mechanisms. At the same time, diagnostic and therapeutic approaches should be improved for a great number of women facing the problem of endometrial hyperplasia. Findings of the international and Russian scientists presented in the article reflect the current understanding of etiology, pathogenesis, diagnosis and treatment of this pathology. Progestogen therapy is pathogenetically justified and has proved to be effective. Among oral progestogens, dydrogesterone has progestogenic antiproliferative activity, an optimal safety profile and allows doctors to personalize therapy for patients with various somatic pathologies in order to control the symptoms of endometrial hyperplasia and prevent recurrence of the disease. Conclusion. Scientific data collection and possibility of providing personalized therapy for patients with endometrial hyperplasia can help improve diagnostics as well as the management of the patients and minimize the risk of recurrence of this pathology.
全文:
作者简介
Natalia Podzolkova
Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
Email: podzolkova@gmail.com
Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology Moscow, Russia
Vera Korennaya
Russian Medical Academy of Continuous Professional Education, Ministry of Health of Russia
Email: drkorennaya@mail.ru
PhD, Associate Professor of the Department of Obstetrics and Gynecology Moscow, Russia
参考
- Mutter L., Zaino R.J., Baak J.P.A., Bentley R.C., Robboy S. Benign Endometrial Hyperplasia Sequence and Endometrial Intraepithelial Neoplasia. International Journal of Gynecological Pathology. 2007; 26(2): 103-14. https://dx.doi.org/10.1097/PGP.0b013e31802e4696.
- Cree I.A., White V.A., Indave B.I., Lokuhetty D. Revising the WHO classification: female genital tract tumours. Histopathology. 2020; 76(1): 151-6. https://dx.doi.org/10.1111/his.13977.
- The American College of Obstetricians and Gynecologists Committee Opinion no. 631. Endometrial intraepithelial neoplasia. Obstet. Gynecol. 2015; 125(5): 1272-8. https://dx.doi.org/10.1097/01.AOG.0000465189.50026.20.
- Reed S.D., Newton K.M., Clinton L., Epplein M., Garcia R., Allison K., Voigt L.F., Weiss N.S. Incidence of endometrial hyperplasia. Am J Obstet Gynecol. 2009; 200(6): 678.e1-6. https://dx.doi.org/10.1016/j.ajog.2009.02.032.
- Lacey Jr. V.L., Chia V.M. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas 2009; 63(1): 39-44. https://dx.doi.org/10.1016/j.maturitas.2009.02.005.
- Ткаченко Л.В., Свиридова Н.И. Гиперпластические процессы эндометрия в перименопаузе: современный взгляд на проблему. Вестник ВолГМУ. 2013; 3(47): 9-15
- Коренная В.В., Масс Е.Е., Колода Ю.А., Полетова Т.Н. Гиперпластические процессы эндометрия: новый взгляд на проблему. Эффективная фармакотерапия. Эндокринология. 2018; 3(26): 34-9
- Auclair M.-H., Yong P.J., Salvador S., Thurston J., Colgan T.J., Sebastianelli A. Guideline No. 392-Classification and Management of Endometrial Hyperplasia. J Obstet Gynaecol Can. 2019; 41(12): 1789-1800. https://doi.org/10.1016/j.jogc.2019.03.025.
- Gallos I.D., Alazzam M., Clark T.J. et al. Management of Endometrial Hyperplasia. RCOG/BSGE Green-top Guideline No. 67. 2016; 67: 2-30. https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guide-lines/gtg_67_endometrial_hyperplasia.pdf.
- Министерство здравоохранения Российской Федерации. Гиперплазия эндометрия. Клинические рекомендации РОАГ, 2021. 35 с. Доступ с сайта: https://roag-portal.ru/clinical_recommendations
- Министерство здравоохранения Российской Федерации. Аномальные маточные кровотечения. Клинические рекомендации РОАГ, 2021. 41 с. Доступ с сайта: https://roag-portal.ru/recommendations_ gynecology
- El Behery M.M., Saleh H.S., Ibrahiem M.A., KamalE.M., Kassem G.A., El Sayed Mohamed M. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. Reprod Sci. 2015; 22(3): 329-34. https://dx.doi.org/10.1177/1933719114542014.
- Максудова Н.М., Исматова М.И., Нурханова Н.О. Коррекция гиперплазии эндометрия у пациенток фертильного возраста c метаболическими нарушениями. Непрерывное медицинское образование и наука. 2015; 10(3): 15-7
- Su C. Reverse of Endometrial Atypical Hyperplasia and Early endometrial carcinoma in PCOS women by Dydrogesterone plus Metformin: a pilot study. Материалы 18-го Всемирного Конгресса «Гинекологическая эндокринология», Флоренция, Италия, 7-10 марта 2018 г.
- Ульрих Е.А., Кутушева Г.Ф., Урманчеева А.Ф. Дюфастон (дидрогестерон) в лечении дисфункциональных маточных кровотечений, ассоциированных с железистой гиперплазией эндометрия. Журнал акушерства и женских болезней. 2003; 52(3): 60-3.
- Соловьева А.В., Чегус Л.А. Аномальные маточные кровотечения у женщин в репродуктивном возрасте и пременопаузе. Акушерство и гинекология. 2020; 8: 29-38
- Соловьева А.В., Ермоленко К.С. Дифференцированный подход к выбору терапии у женщин с аномальными маточными кровотечениями. Акушерство и гинекология. 2018; 3: 157-60
- Дубровина С.О., Киревнина Л.В., Лесной М.Н. Аномальное маточное кровотечение: причины, диагностика и лечение. Акушерство и гинекология. 2021; 1: 170-7
- Дубровина С.О. Рациональный подход к гормональной терапии у женщин старше 40 лет. Акушерство и гинекология. 2019; 7: 112-6
- Подзолкова Н.М., Татарчук Т.Ф., Дощанова А.М., Ешимбетова Г.З., Сумятина Л.В. Нормализация менструального цикла дидрогестероном. Акушерство и гинекология. 2018; 6: 70-6
- Podzolkova N., Tatarchuk T., Doshchanova A., Eshimbetova G., Pexman-Fieth C. Dydrogesterone treatment for menstrual-cycle regularization in routine clinical practice: a multicenter observational study. Gynecol Endocrinol. 2016; 32(3): 246-9. https://dx.doi.org/10.3109/09513590.2015.1115832.
- Trivedi N., Chauhan N., Vaidya V. Effectiveness and safety of dydrogesterone in regularization of menstrual cycle: a post-marketing study. Gynecol Endocrinol. 2016; 32(8): 667-71. https://dx.doi.org/10.3109/09513590.2016.1152238.
- Tajjamal A., Zaman F. Severity of bleeding is a predictor of quality of life in women with heavy menstrual bleeding under dydrogesterone treatment in a prospective, multicentre, observational study. Gazzetta Medica Italiana Archivio per le Scienze Mediche. 2015; 174(9): 391-8.
- Beniuk V.O., Ginzburg V.H., Govsieiev D.O., Oleshko V.F., Kovaliuk T.V., Kravchenko Y.V., Luchko A.S. New approaches to prophylaxis of endometrium hyperplasia relaps in premenopausal women. Reproductive Endocrinology. 2021; 58: 63-72. https://doi.org/10.18370/2309-4117.2021.58.63-72
- Guidelines on Clinical Management of Endometrial Hyperplasia. HKCOG Gudelines Number 16 (September 2015).
- Gadducci A., Spirito N., Baroni E., Tana R., Genazzani A.R. The fertility-sparing treatment in patients with endometrial atypical hyperplasia and early endometrial cancer: a debated therapeutic option. Gynecol Endocrinol. 2009; 25(10): 683-91. https://dx.doi.org/10.1080/09513590902733733.
- Klip H., Burger C.W., van Leeuwen F.E. Risk of hormone-related cancers after ovarian stimulation for in-vitro fertilisation in a cohort of 25,152 women. In: Klip H. (ed). Long Term Health Effects of Subfertility Treatment. Ipskamp BV, Enschede, The Netherlands: Print Partners; 2002. p. 55-82.
- Russo M., Newell J.M., Budurlean L., Houser K.R., Sheldon K., Kesterson J. et al. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma. Cancer. 2020; 126(12): 2775-83. https://dx.doi.org/10.1002/cncr.32822.
- Multinu F., Chen J., Madison J.D., Torres M., Casarin J., Visscher D., Shridhar V. et al. Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer. Gynecol. Oncol. 2020; 156(3): 682-8. https://dx.doi.org/10.1016/j.ygyno.2019.12.023.